How we think about risk in discovery software and early therapeutic framing.
Safety here covers research workflows: biosafety planning for cell and vector work, cardiotoxicity-oriented scoring on public MEA-style data, and dual-use awareness in discovery tooling.
CiPA-aligned research scoring from human iPSC-CM MEA recordings. Useful for structured comparison in MCM and biodefense research contexts.
Six-step BSL planning aid drawing on public CDC, NIH, and WHO guidance for iPSC/ESC-CM and viral-vector style workflows.
They do not replace institutional biosafety committees, formal toxicology packages, regulatory submissions, or clinical judgment. Detailed protocol design remains with qualified laboratories and counsel.
Gene therapy and graft concepts stay in discovery or candidate identification until experimental evidence justifies later stages. Safety filters inform prioritization; they do not certify a product.
Security or safety issues in public repositories: open a GitHub issue on the relevant repo or email virelion85@gmail.com with subject Safety.
